Circulation Journal
Online ISSN : 1347-4820
Print ISSN : 1346-9843
ISSN-L : 1346-9843
Ischemic Heart Disease
Intracoronary Acetylcholine Provocation Testing – Omission of the 20-µg Dose Is Feasible in Patients Without Coronary Artery Spasm in the Other Coronary Artery –
Yuichi SaitoHideki KitaharaToshihiro ShojiSatoshi TokimasaTakashi NakayamaKazumasa SugimotoYoshihide FujimotoYoshio Kobayashi
Author information
JOURNAL FREE ACCESS FULL-TEXT HTML

2016 Volume 80 Issue 8 Pages 1820-1823

Details
Abstract

Background: Based on the Japanese Circulation Society guideline of vasospastic angina, incremental doses of acetylcholine (ACh) are prescribed for coronary spasm provocation: 20 and 50 μg for the right coronary artery (RCA), and 20, 50 and 100 μg for the left coronary artery (LCA). However, the requirement for each dose of ACh has not been fully evaluated.

Methods and Results: A total of 249 patients who underwent ACh provocation test for both the RCA and LCA were included. The positive diagnosis of intracoronary ACh provocation test was defined as total or subtotal coronary artery narrowing accompanied by chest pain and/or ischemic ECG changes. Positive ACh provocation test was observed in 116 patients (47%). Patients without vasospasm in the LCA had a lower incidence of vasospasm in the RCA induced by 20 μg of ACh compared with those with vasospasm in LCA (0.8% vs. 27.5%, P<0.001). Similarly, vasospasm in the LCA induced by 20 μg of ACh was observed less frequently in patients without than with vasospasm in the RCA (6.1% vs. 26.7%, P<0.001). In all patients without vasospasm in the other coronary artery, intracoronary administration of 50 μg of ACh was performed without any complications.

Conclusions: Skipping the provocation test with 20 μg of ACh in patients without coronary artery spasm in the other coronary artery may be possible. (Circ J 2016; 80: 1820–1823)

Vasospastic angina (VA) is an important cardiac disorder that causes myocardial infarction, ventricular arrhythmia, or sudden cardiac arrest.13 Although the intracoronary acetylcholine (ACh) provocation test is useful for diagnosing VA,4,5 there are various protocols in terms of the doses of ACh.4,6,7 Based on the guidelines of the Japanese Circulation Society for the diagnosis and treatment of patients with VA, incremental doses of ACh are prescribed for the coronary artery vasospasm provocation test: 20 and 50 μg for the right coronary artery (RCA), and 20, 50 and 100 μg for the left coronary artery (LCA).8 However, the requirement for each dose of ACh to provoke coronary artery vasospasm has not been fully evaluated.

Methods

Study Population

A total of 269 consecutive patients underwent the intracoronary ACh provocation test from April 2012 to December 2014 at Chiba University Hospital. Patients who underwent the ACh provocation test only for the RCA (n=2) or LCA (n=15) were excluded. Patients who received a single dose of 10 μg of ACh for the RCA (n=1) and 100 μg for the LCA (n=2) were also excluded. Thus, 249 patients who underwent the ACh provocation test for both the RCA and LCA were included in this study. Written informed consent for examination was given by all patients, and the Ethics Committee of Chiba University approved this study.

Intracoronary ACh Provocation Test

Intracoronary ACh provocation tests were performed according to the guidelines of the Japanese Circulation Society Joint Working Group for the diagnosis and treatment in the clinical setting of patients with VA.8 In elective cases, all vasodilators, such as calcium-channel blockers and long-acting nitrates, were discontinued at least 48 h before the examination, except for sublingual nitroglycerin as needed. After insertion of a temporary pacing electrode in the right ventricle, control angiography of the LCA and RCA was performed. ACh was injected in incremental doses of 20 and 50 µg into the RCA, and 20, 50 and 100 μg into the LCA over a period of 20 s. Coronary angiography (CAG) was performed 1 min after the start of each injection. In the event of an ischemic change on ECG or chest pain, CAG was performed at that time. Doses of ACh were given at 5-min intervals. After the ACh provocation test, 1 mg of isosorbide dinitrate was administered into the RCA and LCA, and CAG was then performed.

Definitions

Angiographic coronary artery vasospasm was defined as total or subtotal occlusion induced by the ACh provocation test. It was evaluated by 2 experienced cardiologists, who were unaware of the patients’ clinical characteristics. A positive diagnosis was defined as angiographic coronary artery vasospasm accompanied by chest pain and/or ischemic ECG changes, such as transient ST elevation ≥0.1 mV, ST depression ≥0.1 mV, or new appearance of negative U waves, recorded in at least 2 contiguous leads on the 12-lead ECG.8 Multivessel spasm was defined as ACh-induced coronary artery vasospasm in ≥2 major epicardial arteries. Cardiac complications were defined as death, ventricular fibrillation or tachycardia, and cardiogenic shock by ACh provocation test.

Statistical Analysis

Statistical analysis was performed with SAS statistical software package version 9.4 (SAS Institute, Cary, NC, USA). Data are expressed as mean±SD or frequency (%). Categorical variables were compared with Fisher’s exact test. A value of P<0.05 was considered significant.

Results

Table 1 presents the patients’ baseline characteristics. There were 91 patients with ECG changes and 126 patients with chest symptoms during the ACh provocation test. In these patients, 83 (91%) and 108 patients (86%) were accompanied by angiographic vasospasm. A positive ACh provocation test was observed in 116 patients (47%) (Table 2). Table 3 shows cardiac complications associated with ACh provocation tests. Although 1 case of ventricular tachycardia was documented in each of the LCA and RCA, both spontaneously terminated. Cardiogenic shock occurred in 1 patient by ACh provocation of the LCA, caused by diffuse severe vasospasm at both the left descending and circumflex arteries with rapid lowering of systolic blood pressure to 50 mmHg, followed by inevitable intravenous administration of noradrenaline.

Table 1. Characteristics of the Study Patients Undergoing the ACh Provocation Test (n=249)
Age (years) 63.6±11.7
Men 138 (55%)
Body mass index (kg/m2) 24.0±4.5
Hypertension 164 (66%)
Diabetes mellitus 52 (21%)
Dyslipidemia 180 (72%)
Current smoker 52 (21%)
Prior myocardial infarction 32 (14%)
Clinical presentation
 Rest angina 173 (69%)
 Effort angina 8 (3%)
 Rest and effort angina 52 (21%)
 No angina 16 (6%)
Medical treatment
 Calcium-channel blocker 121 (49%)
 Long-acting nitrate 46 (19%)
 Antiplatelet drug 84 (34%)
 Statin 94 (38%)
 ACEI or ARB 91 (37%)
 β-blocker 37 (15%)

ACEI, angiotensin-converting enzyme inhibitor; ACh, acetylcholine; ARB, angiotensin-receptor blocker.

Table 2. ACh Provocation Test (n=249)
Initial artery of ACh provocation
 Right coronary artery 16 (6%)
 Left coronary artery 233 (94%)
No. of vessels with vasospasm
 0 108 (43%)
 1 68 (27%)
 2 53 (21%)
 3 20 (8%)
Multivessel spasm 73 (29%)
Provoked coronary artery
 Right 86 (35%)
 Left anterior descending 114 (46%)
 Left circumflex 34 (14%)
Evidence of ischemia
 ECG change 83 (33%)
 Chest pain 108 (43%)
Positive ACh provocation test 116 (47%)

ACh, acetylcholine.

Table 3. Cardiac Complications of Study Patients Undergoing the ACh Provocation Test
  Left coronary artery Right coronary artery
20 μg 50 μg 100 μg 20 μg 50 μg
Death 0 0 0 0 0
Cardiogenic shock 0 0 1 (0.5%) 0 0
Ventricular tachycardia 0 0 1 (0.5%) 0 1 (0.6%)

ACh, acetylcholine.

Patients without vasospasm in the LCA had a lower incidence of vasospasm in the RCA induced by 20 μg of ACh compared with those with vasospasm in the LCA (0.8% vs. 27.5%, P<0.001) (Figure 1). In all patients without vasospasm in the LCA, intracoronary administration of 50 μg of ACh was performed, regardless of vasospasm induced by 20 μg of ACh in the RCA, without any complications associated with administration of ACh. Similarly, vasospasm in the LCA induced by 20 μg of ACh was observed less frequently in patients without than with vasospasm in the RCA (6.1% vs. 26.7%, P<0.001) (Figure 2). In addition, the incidence of vasospasm in the RCA by 20 μg of ACh in patients without vasospasm in the LCA was significantly lower than that of vasospasm in the LCA by 20 μg of ACh in patients without vasospasm in the RCA (0.8% vs. 6.1%, P=0.03).

Figure 1.

Occurrence of coronary artery vasospasm by incremental doses of acetylcholine (ACh) in the right coronary artery (RCA) based on the result of the provocation test in the left coronary artery (LCA).

Figure 2.

Occurrence of coronary artery vasospasm by incremental doses of acetylcholine (ACh) in the left coronary artery (LCA) based on the result of the provocation test in the right coronary artery (RCA).

In all patients without vasospasm in the RCA, the intracoronary administration of 50 μg of ACh was performed, regardless of vasospasm induced by 20 μg of ACh in the LCA, without any complications associated with administration of ACh.

Discussion

The main finding of the present study was that vasospasm was induced infrequently by administration of 20 μg of ACh in patients without coronary artery spasm in the other coronary artery, especially in patients without vasospasm in the LCA. In patients with a positive provocation test with 20 μg of ACh and no vasospasm in the other coronary artery, provocation test with 50 μg of ACh was performed without any complications. Thus, ACh provocation probably should be performed initially for the LCA according to the guidelines by Japanese Circulation Society,8 leading to skipping of the provocation test with 20 μg of ACh for the RCA to reduce contrast volume and procedure time in cases of no vasospasm in the LCA.

ACh Provocation Doses

The intracoronary ACh provocation test is a validated method of diagnosing VA,4,9 with few serious complications.10,11 A variety of protocols, in terms of ACh doses, have been used,4,6,7 but there are few reports evaluating these doses of ACh. Although the guidelines of the Japanese Circulation Society for the diagnosis and treatment of patients with VA recommend administering incremental doses of ACh, sometimes that is not done in Japanese clinical settings.6 Sueda et al showed that 16% of the hospitals used a single dose of ACh for each coronary artery (ie, 50 μg for the RCA and 100 μg for the LCA). Furthermore, the usefulness of higher doses of ACh such as 80 μg for the RCA and 200 μg for the LCA has recently been demonstrated.7,11,12 In the present study, 2 cases of ventricular tachycardia and one of cardiogenic shock were documented, and all of them were induced by the maximum dose of ACh for each of the coronary arteries (LCA and RCA). Therefore, it is suggested that the first target artery should always be examined with incremental doses of ACh to avoid serious complications, because the provocation test by the incremental doses may be able to detect the threshold of vasospastic activity in individual patients.

Multivessel coronary spasm is a prognostic factor of patients with vasospasm.13,14 On the other hand, previous studies have shown relatively low disease activity in patients without vasospasm by provocation test in either coronary artery.11,12,15 Thus, a provocation test with 50 μg of ACh as the first dose may be performed safely in patients without vasospasm in the other coronary artery.

In patients with vasospasm in the other coronary artery, it might also be possible that a provocation test with 50 μg of ACh as the first dose could be safely performed. In the present study population, however, 1 patient with vasospasm in the LCA developed ventricular tachycardia after provocation with 50 μg of ACh in the RCA. In addition, 2 of the 86 patients with vasospasm in the LCA and 6 of the 120 patients with vasospasm in the RCA did not receive intracoronary administration of 50 μg of ACh in the other coronary artery, because sufficient provocation was achieved by 20 μg of ACh. Therefore, it is still unclear whether the provocation test with 50 μg of ACh as the first dose can be safely conducted in patients with vasospasm in the other coronary artery.

Study Limitations

First, the number of patients was relatively small. Second, patients with a provocation test for only one coronary artery were excluded. Third, intracoronary ACh provocation tests were not performed in the morning in any of the patients, especially those in an unstable condition. There is a circadian variation in the occurrence of coronary vasospasm.16,17 Further investigation is required for this issue.

Conclusions

During VA evaluation, patients without coronary artery spasm in the other coronary artery may be able to skip the provocation test of 20 μg of ACh, thereby using less contrast and shortening the overall procedure time.

Disclosure

None.

References
 
© 2016 THE JAPANESE CIRCULATION SOCIETY
feedback
Top